The leukemic oncoprotein NPM1-RARA inhibits TP53 activity

References

• Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93: 3167–3215.
   PubMed Web of Science ®Google Scholar
• Redner RL. Variations on a theme: the alternate translocations in APL. Leukemia. 2002;16:1927–1932.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 1993;12:1161–1167.
   PubMed Web of Science ®Google Scholar
• Redner RL, Rush EA, Faas S, et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996;87:882–886.
   PubMed Web of Science ®Google Scholar
• Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997;17:109–113.
   PubMed Web of Science ®Google Scholar
• Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8: 1741–1749.
   PubMed Web of Science ®Google Scholar
• Catalano A, Dawson MA, Somana K, et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 2007;110:4073–4076.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Tsuzuki S, Tsuzuki M, et al. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood. 2010;116:4274–4283.
   PubMed Web of Science ®Google Scholar
• Kondo T, Mori A, Darmanin S, et al. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica. 2008;93:1414–1416.
   PubMed Web of Science ®Google Scholar
• Won D, Shin SY, Park CJ, et al. OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia. Blood. 2013;121:1432–1435.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li S, Zhou C, et al. TBLR1 fuses to retinoid acid receptor alpha in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia. Blood. 2014;124:936–945.
   PubMed Web of Science ®Google Scholar
• Corey SJ, Locker J, Oliveri DR, et al. A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features. Leukemia. 1994;8:1350–1353.
   PubMed Web of Science ®Google Scholar
• Redner RL, Corey SJ, Rush EA. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia. 1997;11:1014–1016.
   PubMed Web of Science ®Google Scholar
• Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene. 2011;30:2595–2609.
   PubMed Web of Science ®Google Scholar
• Okuwaki M. The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem. 2008;143:441–448.
   PubMed Web of Science ®Google Scholar
• Du C, Redner RL, Cooke MP, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood. 1999;94:793–802.
   PubMed Web of Science ®Google Scholar
• Pollock SL, Rush EA, Redner RL. NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation. Leuk Lymphoma. 2014;55:1383–1387.
   PubMed Web of Science ®Google Scholar
• Rego EM, Ruggero D, Tribioli C, et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene. 2006;25:1974–1979.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay A, Hood BL, Conrads TP, Redner RL. Extrinsic apoptosis is impeded by direct binding of the APL fusion protein NPM-RAR to TRADD. Mol Cancer Res. 2014;12:1283–1291.
   PubMed Web of Science ®Google Scholar
• Rush EA, Schlesinger KW, Watkins SC, Redner RL. The NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML. Leuk Res. 2006;30: 979–986.
   PubMed Web of Science ®Google Scholar
• Redner RL, Chen JD, Rush EA, et al. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. Blood. 2000;95:2683–2690.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay A, Abecassis I, Redner RL. NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFkappaB and JNK. Leuk Lymphoma. 2015;56:3401–3406.
   PubMed Web of Science ®Google Scholar
• Rush EA, Pollock SL, Abecassis I, Redner RL. Interaction with RXR is necessary for NPM-RAR-induced myeloid differentiation blockade. Leuk Res. 2013;37:1704–1710.
   PubMed Web of Science ®Google Scholar
• Waterhouse NJ, Trapani JA. A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ. 2003;10:853–855.
   PubMed Web of Science ®Google Scholar
• Grandela C, Pera MF, Grimmond SM, et al. p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Stem Cell Res. 2007;1:116–128.
   PubMed Web of Science ®Google Scholar
• Insinga A, Monestiroli S, Ronzoni S, et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 2004;23:1144–1154.
   PubMed Web of Science ®Google Scholar
• Colombo E, Marine JC, Danovi D, et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4:529–533.
   PubMed Web of Science ®Google Scholar
• Lambert B, Buckle M. Characterisation of the interface between nucleophosmin (NPM) and p53: potential role in p53 stabilisation. FEBS Lett. 2006;580:345–350.
   PubMed Web of Science ®Google Scholar
• Brady SN, Yu Y, Maggi LB Jr., Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol. 2004;24:9327–9338.
   PubMed Web of Science ®Google Scholar
• So CW, Dong S, So CK, et al. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. Leukemia. 2000;14:77–83.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–1284.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–266.
   PubMed Web of Science ®Google Scholar
• Ablain J, Rice K, Soilihi H, et al. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 2014;20: 167–174.
   PubMed Web of Science ®Google Scholar